Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CYTK
CYTK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CYTK News
Cytokinetics Awards Grants to Patient Advocacy Organizations
6d ago
Newsfilter
Cytokinetics Board Faces Claims of Breach of Fiduciary Duty as Stock Plummets
Jan 22 2026
Businesswire
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Cytokinetics (CYTK) and FuboTV (FUBO) Options Volume Surge
Jan 12 2026
NASDAQ.COM
Cytokinetics Faces Shareholder Investigation Over Alleged Misleading Statements
Jan 02 2026
Globenewswire
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
Dec 31 2025
Benzinga
Cytokinetics Faces Shareholder Investigation Over Alleged Misstatements
Dec 30 2025
Globenewswire
Edgewise Therapeutics Updates EDG-7500 Phase 2 Trial Progress, Shares Rise 17.96%
Dec 24 2025
Benzinga
CYTK Receives FDA Approval for Myqorzo, Launch Expected in 2026
Dec 22 2025
Newsfilter
Cytokinetics Receives FDA Approval for Myqorzo to Treat Heart Disease
Dec 22 2025
Benzinga
UniFirst Corp Receives $275 Acquisition Proposal from Cintas, Valuing Company at $5.2 Billion
Dec 22 2025
Benzinga
Cytokinetics Faces Shareholder Claims Over Executive Misconduct, Potential for Corporate Reforms
Dec 22 2025
Globenewswire
JP Morgan Cuts Paychex Price Target to $125 Amid Underweight Rating
Dec 22 2025
Benzinga
Does the First U.S. MYQORZO Approval Alter the Investment Outlook for Cytokinetics (CYTK)?
Dec 20 2025
Yahoo Finance
Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
Dec 20 2025
NASDAQ.COM
FDA Grants Approval for Cytokinetics' MYQORZO to Treat Obstructive Hypertrophic Cardiomyopathy
Dec 20 2025
NASDAQ.COM
Show More News
